The metabolic syndrome, which covers a wide variety of pathological concerns, is rapidly becoming a global pandemic.

The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of a constellation of metabolic abnormalities that confer increased risk of cardiovascular disease (CVD). Metabolic syndrome is defined as the occurrence of three abnormal results out of five components: elevated waist circumference, elevated triglycerides, reduced high density lipoprotein cholesterol, elevated blood pressure, and elevated fasting plasma glucose.

Current therapeutic options for metabolic syndrome are limited to individual treatment for hypertension, hyperglycemia and hypertriglyceridemia, as well as dietary control measures and regular exercise, including water-based training.

Repetitive transcranial magnetic stimulation (rTMS) is a safe and non-invasive neuromodulation technique that may reduce the food craving levels in obese patients by changing cortical brain activity. TMS alone or in combination with other anti-obesity approaches may open new ways to sustain the efficacy of weight control interventions.

As part of this pilot study, the parameters like weight change, changes in food craving levels, and cardiometabolic risk factors like fasting lipid levels, total cholesterol, high-density lipoproteins, low-density lipoproteins, fasting glucose levels and high sensitivity C- reactive protein, along with food craving questionnaires will be measured at the end of the therapy and on three follow up visits at the end of fifteen days, one month and three months after the end of the therapy.